Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Die Untersuchung der Brandursache der U1 war nur einer von bis zu 1.500 Fällen pro Jahr, in denen die Beamten und Beamtinnen des Ermittlungsbereichs 8 (EB 08) ermitteln. 2014 gegründet sind mittlerwei ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...